Corteva Invests in a Post-Chemical Future

Corteva backs Ascribe Bio's $12M Series A and inks an R&D deal to advance next-gen biofungicide seed treatments for US growers

6 Mar 2026

Synthetic fungicides have long been the workhorses of crop protection. They are reliable, scalable, and increasingly problematic: resistance is spreading, and regulators are tightening. Into this gap steps Ascribe Bio, a small startup from Ithaca, New York, with a product derived not from a laboratory bench but from molecules already present in the soil.

In October 2025, Corteva co-led a $12m Series A funding round for Ascribe Bio through Corteva Catalyst, its venture arm. The round was oversubscribed, drawing in Syngenta Group Ventures, Acre Venture Partners, and Trailhead Capital, among others. Then, in March 2026, Corteva took the relationship further, signing a multi-year research and development agreement with the startup.

The commercial logic is straightforward. Ascribe Bio's product, Phytalix, is built on ascarosides: small molecules found in the soil microbiome. Rather than attacking fungal pathogens directly, it works by priming the plant's own immune defences. This mode of action, its backers argue, sidesteps the resistance problems that undermine conventional fungicides. With more than 500 field trials completed and regulatory approval pending in the United States, the product is closer to market than most early-stage biological candidates.

Under the collaboration, Ascribe Bio leads laboratory work and early field trials while Corteva contributes formulation know-how, seed treatment infrastructure, and agronomic testing across major growing regions. The goal is to extend Phytalix beyond foliar applications and into seed treatments for corn, wheat, and soybeans: a significantly larger addressable market.

For Corteva, the deal feeds an existing ambition. The company has set a target of $1bn in annual biologicals revenue by 2030, and its 2025 results showed crop-protection volume growth supported by new biological products. A planned separation of its crop-protection business, expected in the second half of 2026, is designed to sharpen strategic focus.

Whether biological products can genuinely displace synthetic fungicides at scale, rather than merely supplement them, remains an open question. Capital confidence, for now, is running ahead of proof.